期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替罗非班治疗急性冠脉综合征临床观察 被引量：1

下载PDF
导出
摘要 目的观察血小板GPⅡb/Ⅲa受体拮抗剂替罗非班治疗急性冠脉综合征(ACS)的临床效果和安全性。方法70例急性冠脉综合征患者随机、双盲分为替罗非班静脉应用组(n=35)与常规治疗组(n=35),疗程36小时,终点事件是36h和30天的复合缺血事件(死亡、新发心梗、顽固心肌缺血)。结果36h及30天的复合缺血事件发生率,受试组低于对照组(36h:2.9%vs22.9%,30天:5.7%vs35.7%,P<0.001),替罗非班组肌钙蛋白T(cTnT)峰值水平明显低于对照组,出血并发症在两组之间差异无显著性(P>0.05)。结论替罗非班在ACS标准治疗基础上能进一步减少心肌缺血事件,并能减少心肌细胞的损伤,且安全性较好。
作者 赵依农 吾红光 邱慧卿 杨淳英 郑彦
机构地区 衢州市衢江区人民医院心内科
出处 《心脑血管病防治》 2008年第4期241-242,共2页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
关键词 GPⅡb/Ⅲa受体拮抗剂 替罗非班 急性冠脉综合征
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献6

  • 1Vorchheiner DA, Badimon JJ, Fuster V. Platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonists in cardiovascular disease[J]. JAMA, 1999,281 ( 15): 1407 - 1414.
  • 2James C. Bleeding complications of glycoprotein Ⅱb/Ⅲa receptor inhibitors[J]. Am Heart J, 1999, 138:287-294.
  • 3Boersma E,Harrington RA,Molitemo DJ,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes[J].Lancet,2002,359:189-198.
  • 4Lindahl B, Venge P, Wallenfin L. Relation between ttroponinT and the risk of subsequent cardiac events in unstable coronary artery disease[J]. Circulation, 1996,93:1651 - 1657.
  • 5杨晓燕,龚培力,王琳,李芳,王朝晖,王秋芬,陈健,党瑜华,赵洛沙,许爱国,刘鹏.替罗非班治疗急性冠状动脉综合征的疗效和安全性评价[J].中国医院药学杂志,2006,26(3):275-278. 被引量：29
  • 6侯玉清,周忠江,黎建勇,贾满盈,吴平生,刘伊丽,滕中华.国产替罗非班治疗急性冠状动脉综合征的临床研究[J].中国介入心脏病学杂志,2007,15(1):34-36. 被引量：25

二级参考文献12

  • 1The RESTORE Investigators.Effects of platelet glycoprotein Ⅱ a/Ⅲ b blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J].Circulation,1997,96:1445-1453.
  • 2Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina[J].N Engl J Med,1998,338:1498-1505.
  • 3Fuster V,Badimon L,Badimon JJ,etal.The pathogenesis of coronary artery disease and the acute coronary syndromes[J].N Engl J Med,1992,326:242-250.
  • 4The PRISM-PLUS Study Investigators.Inhibition of the platelet glycoprotein b/a receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction[J].N Engl J Med,1998,338:1488-1497.
  • 5Kimmelstiel C,Badar J,Covic L,et al.Pharmacodynamics and pharmacokinetics of the platelet GPⅡb/Ⅲa inhibitor tirofiban in patients undergoing percutaneous coronary intervention:implications for adjustment of tirofiban and clopidogrel dosage.Thromb Res,2005,116:55-66.
  • 6Ernst NM,Suryapranata H,Miedema K,et al.Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.J Am Coll Cardiol,2004,44:1187-1193.
  • 7Morrow DA,Sabatine MS,Antman EM,et al.Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).Am J Cardiol,2004,94:774-776.
  • 8Valgimigli M,Percoco G,Barbieri D,et al.The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty:the ADVANCE Trial.J Am Coll Cardiol,2004,44:14-19.
  • 9Wyss CA,Roffi M.Platelet Inhibition in Percutaneous Coronary Interventions.Herz,2005,30:189-196.
  • 10The PRISM-PLUS investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl J Med,1998,338:1488.

共引文献47

同被引文献12

引证文献1

心脑血管病防治
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部